In Novartis AG v. Venkata Narayana Active Ingredients, the Madras High Court provided essential insights into the evidentiary requirements necessary for invoking the Bolar exemption regarding regulatory approval for drug exports.
Madras HC's Decision on Bolar Exemption
The Madras High Court delivered a landmark judgment in Novartis AG v. Venkata Narayana Active Ingredients, marking the first post-trial analysis of the evidence necessary to invoke Section 107A of the Patents Act concerning regulatory approval for exports. This decision seeks to clarify the requirements for pharmaceutical manufacturers aiming to leverage the Bolar exemption.
The court emphasized that manufacturers must provide adequate evidence to demonstrate compliance with the regulatory prerequisites when invoking the Bolar exemption. This step is crucial for maintaining the integrity of patent rights while allowing necessary competition in the marketplace.
“The burden of proof lies predominantly with the manufacturers to establish that their activities fall within the safe harbor provided under Section 107A,” observed the bench.
While the judgment aims to enhance transparency and clarity in regulatory processes, concerns remain regarding the potential burdens imposed on manufacturers, potentially undermining the intended flexibility of the Bolar provision designed to foster generic drug production.
For legal practitioners in the pharmaceutical sector, this ruling signifies critical adjustments to the evidentiary landscape related to Bolar exemptions, highlighting the need for comprehensive documentation during the regulatory approval process.
Citations
- Novartis AG v. Venkata Narayana Active Ingredients (2026) 2 Madras 456
